Jazz Pharmaceuticals plc (JAZZ): Results of Operations and Financial Condition
Jazz Pharmaceuticals plc (JAZZ) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26financialpr.htm EX-99.1 Document Exhibit 99.1 Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results – Continued commercial execution drives record total revenues of $1.2 billion (+16% YoY) – – Company raises 2026 revenue guidance – – Prepared to laun
How this was made
The 30-second read
Why it matters
The combination of a same-day guidance raise, record quarterly revenues, and a specific FDA PDUFA date for zanidatamab sBLA creates a clear near-term catalyst path for earnings expectations and risk premium.
Market read
Traders can reprice JAZZ based on the raised 2026 revenue guidance and the defined FDA timeline for zanidatamab sBLA, alongside updated product sales momentum.
What to watch
The filing notes planned Zepzelca labeling supplement to remove the second-line indication in 3Q26, which could temper longer-term revenue expectations even as first-line maintenance remains unaffected.
Background
This SEC 8-K item 2.02 attaches Jazz’s 2Q26 financial results and business updates, including FDA regulatory timelines and guidance.
Ticker impact
Jazz reported 2Q26 results and raised 2026 revenue guidance to $4.60 to $4.75 billion, citing strong Xywav and Epidiolex growth.
Likely positive bias for the stock into the Aug 25, 2026 PDUFA date and as investors model the raised 2026 revenue range.
The filing includes concrete financial datapoints (2Q26 revenue, EPS, cash from operations) and a specific guidance increase, plus a scheduled FDA action date for zanidatamab sBLA and a planned Ziihera launch immediately after approval.
Market effects
Reinforces demand momentum in specialty pharma neurology and epilepsy franchises, potentially supporting sentiment for peers with similar commercial execution.
Primarily US-focused due to FDA action date and US commercial metrics, with limited direct regional spillover.
Modest global read-through, as the catalysts are US regulatory and US revenue drivers.
Counterpoint
Raised guidance may already be partially anticipated; investors could focus on the smaller near-term Ziihera revenue base ($15M BTC sales) versus the larger upside implied by future HER2+ 1L launch.
Key entities
- issuerJazz Pharmaceuticals plc
Reported 2Q26 financial results, raised 2026 revenue guidance, and provided FDA and launch timing for Ziihera (zanidatamab).
- product_programZiihera (zanidatamab-hrii)
Prepared to launch in HER2+ 1L GEA immediately following FDA approval, with PDUFA target action date of Aug 25, 2026.
- productXywav (calcium, magnesium, potassium, and sodium oxybates)
2Q26 net product sales grew 13% YoY to $471M with ~525 net patient adds.
- productEpidiolex/Epidyolex (cannabidiol)
2Q26 net product sales grew 16% YoY to $292M, with expanded development program and NDA submission for capsule formulation.
- product_programZepzelca (lurbinectedin)
2Q26 net product sales increased 42% YoY to $106M; company plans a labeling supplement in 3Q26 to remove second-line indication.
